Eterna Therapeutics posts FY2022 net loss $24.6M; licenses iPSC tech to Lineage, subleases BMS space

Ernexa Therapeutics Inc.

Net loss for Q4 2022 was $4.5M ($1.24 per share); full year net loss $24.6M ($8.06 per share).
Cash and restricted cash $15.5M as of Dec 31, 2022; $4.1M restricted for BMS sublease.
Entered income-generating license agreement with Lineage Cell Therapeutics for gene-edited iPSC lines for neurology indications.
Subleased 45,000 sq. ft. from BMS at Cambridge Crossing; BMS provides $8.6M for build-out.
Appointed Matt Angel, Ph.D. as permanent CEO and President (previously interim).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Ernexa Therapeutics Inc. reported full year of 2022 results: net income For the full year of 2022, net loss was $24.6 million, or $8.06 per share., EPS $8.06 per share.

Period: full year of 2022
Net income: For the full year of 2022, net loss was $24.6 million, or $8.06 per share.
EPS: $8.06 per share
Result: reported results

Exact text from the filing

For the full year of 2022, net loss was $24.6 million, or $8.06 per share.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Ernexa Therapeutics Inc. reported fourth quarter of 2022 results: net income Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share, EPS $1.24 per share.

Period: fourth quarter of 2022
Net income: Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share
EPS: $1.24 per share
Result: reported results

Exact text from the filing

Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share.

View on SEC.gov

Browse all earnings releases →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-012545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.